BEGIN:VCALENDAR VERSION:2.0 PRODID:-//swoogo.com//NONSGML kigkonsult.se iCalcreator 2.27.21// CALSCALE:GREGORIAN BEGIN:VEVENT UID:3afba95f5aba169e87841a79a4a07e951a6cabf2@swoogo.com DTSTAMP:20240329T141955Z DESCRIPTION:CDMOs are becoming increasingly assertive in their negotiation of contracts with pharmaceutical companies. This trend may be the result o f the rise of the CDMO model\, as well as the influx of private equity int o this market segment. Regardless of the reason\, pharmaceutical companies should now expect CDMOs to be more aggressive in contractually protecting themselves.\n\nSPONSORED BY:\n\n [https://rodmanmedia.swoogo.com/cp-webse ries/cmic]\n DTSTART:20200924T170000Z DTEND:20200924T180000Z LAST-MODIFIED:20240329T141955Z LOCATION:https://rodmanmedia.swoogo.com/cp-webseries/v/s-320256 SEQUENCE:0 STATUS:CONFIRMED SUMMARY:Understanding Your CDMO: A Legal Perspective on Quality Agreements TRANSP:OPAQUE X-ALT-DESC;FMTTYPE=text/html:
CDMOs are becoming increasingly assertive i n their negotiation of contracts with pharmaceutical companies. This trend may be the result of the rise of the CDMO model\, as well as the influx o f private equity into this market segment. Regardless of the reason\, phar maceutical companies should now expect CDMOs to be more aggressive in cont ractually protecting themselves.
\n\nSponsored by:< /p>\n\n
BEGIN:VALARM ACTION:DISPLAY DESCRIPTION:CDMOs are becoming increasingly assertive in their negotiation of contracts with pharmaceutical companies. This trend may be the result o f the rise of the CDMO model\, as well as the influx of private equity int o this market segment. Regardless of the reason\, pharmaceutical companies should now expect CDMOs to be more aggressive in contractually protecting themselves.\n\nSPONSORED BY:\n\n [https://rodmanmedia.swoogo.com/cp-webse ries/cmic]\n TRIGGER:-PT30M END:VALARM END:VEVENT END:VCALENDAR